Profile
| Metric | Value |
|---|---|
| Full Name | 10x Genomics, Inc. |
| Ticker | NASDAQ: TXG |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Health Information Services |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | 10xgenomics.com |
| Employees | 1,306 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $18.32 | |
| Price, 1D Change | +10.23% | |
| Market Cap | $2B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.90 | |
| Revenue | $611M | |
| Revenue, 1Y Change | -1.28% | |
| EPS | -$1.52 | |
| EPS, 1Y Change | +30.36% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:2 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$1.52 | |
| EPS Estimate | -$0.05 | |
| EPS Est. Change | +96.92% | |
| Revenue | $610.79M | |
| Revenue Estimate | $632.78M | |
| Revenue Est. Change | +3.60% | |
| Current Price | $18.32 | |
| Price Target | - | $17.50 |
| Price Tgt. Change | - | -4.48% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.12 | -$2.18 | -2.70% | |
| -$0.61 | -$1.52 | -147.22% | |
| -$0.05 | N/A | +96.92% | |
| -$0.41 | N/A | +72.96% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $616.90M | $618.73M | +0.30% | |
| $610.74M | $610.79M | +0.01% | |
| $632.78M | N/A | +3.60% | |
| $610.93M | N/A | +0.02% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +17.44% | |
| Price, 3Y | -51.24% | |
| Market Cap, 1Y | +21.53% | |
| Market Cap, 3Y | -46.43% | |
| Revenue, 1Y | -1.28% | |
| Revenue, 3Y | +24.53% | |
| EPS, 1Y | +30.36% | |
| EPS, 3Y | -187.38% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $18.32 | |
| SMA 200 | $12.39 | |
| SMA 200 vs Price | -32.35% | |
| SMA 50 | $16.14 | |
| SMA 50 vs Price | -11.88% | |
| Beta | 1.90 | |
| ATR | $0.87 | |
| 14-Day RSI | 64.34 | |
| 10-Day Volatility | 61.10% | |
| 1-Year Volatility | 71.61% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $610.79M | |
| EPS | -$1.52 | |
| Gross Profit | $414.48M | |
| Gross Margin | 67.86% | |
| Operating Profit | -$194.56M | |
| Operating Margin | -31.85% | |
| Net Income | -$182.63M | |
| Net Margin | -29.90% | |
| EBITDA | -$133.99M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| Current Ratio | 4.97 | |
| Quick Ratio | 4.26 | |
| Interest Coverage | -44.42K | |
| F-Score | 3 | |
| Altman Z-Score | 5.07 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 3.61 | |
| PB Ratio | 2.95 | |
| EV/EBITDA | -19.52 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $710.13M | |
| Cash & Equivalents | $344.07M | |
| Total Assets | $918.64M | |
| Current Assets | $584.39M | |
| Total Liabilities | $208.50M | |
| Current Liabilities | $117.63M | |
| Total Debt | $82.61M | |
| Short Term Debt | $9.29M | |
| Accounts Payable | $12.91M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $805.34M | |
| Operating Expenses | $609.04M | |
| Cost Of Goods Sold | $196.30M | |
| SG&A | $344.34M | |
| D&A | $43.71M | |
| Interest Expense | $4,000.00 | |
| Income Tax | $4.93M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $6.66M | |
| CFI | -$32.63M | |
| CFF | $10.91M | |
| Capex | $13.39M | |
| Free Cash Flow | -$6.73M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Canaccord Genuity | → | |
| Barclays | → | |
| Citigroup | → | |
| Morgan Stanley | → | |
| Piper Sandler | → | |
| UBS | → | |
| JP Morgan | → | |
| Canaccord Genuity | → | |
| Barclays | → | |
| Piper Sandler |
Analyst sentiment
Institutional ownership
Screeners with TXG
Data Sources & References
- TXG Official Website www.10xgenomics.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1770787/000162828025050332/0001628280-25-050332-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1770787/000177078725000013/0001770787-25-000013-index.htm
- TXG Profile on Yahoo Finance finance.yahoo.com/quote/TXG
- TXG Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/txg
FAQ
What is the ticker symbol for 10x Genomics, Inc.?
The ticker symbol for 10x Genomics, Inc. is NASDAQ:TXG
Does 10x Genomics, Inc. pay dividends?
No, 10x Genomics, Inc. does not pay dividends
What sector is 10x Genomics, Inc. in?
10x Genomics, Inc. is in the Healthcare sector
What industry is 10x Genomics, Inc. in?
10x Genomics, Inc. is in the Health Information Services industry
What country is 10x Genomics, Inc. based in?
10x Genomics, Inc. is headquartered in United States
When did 10x Genomics, Inc. go public?
10x Genomics, Inc. initial public offering (IPO) was on September 12, 2019
Is 10x Genomics, Inc. in the S&P 500?
No, 10x Genomics, Inc. is not included in the S&P 500 index
Is 10x Genomics, Inc. in the NASDAQ 100?
No, 10x Genomics, Inc. is not included in the NASDAQ 100 index
Is 10x Genomics, Inc. in the Dow Jones?
No, 10x Genomics, Inc. is not included in the Dow Jones index
When was 10x Genomics, Inc. last earnings report?
10x Genomics, Inc.'s most recent earnings report was on November 6, 2025
When does 10x Genomics, Inc. report earnings?
The next expected earnings date for 10x Genomics, Inc. is February 11, 2026